GlassScriptPhysician profile
Venkat Reddy
NPI 1720134521
$5,851.27
in general payments reported to CMS, 2019-2025
30 companies · $523 in 2025
The $523 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $861 · 2021: $797 · 2022: $1,322 · 2023: $552 · 2024: $1,259 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,231.44 | 2020-2024 | Epic, Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $698.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Medtronic Vascular, INC. | $583.26 | 2020 | |
| Indivior INC. | $282.34 | 2019-2025 | Sublocade |
| Novo Nordisk INC | $272.86 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $220.81 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Atricure, INC. | $196.12 | 2024 | |
| Astellas Pharma US INC | $184.05 | 2019-2025 | Veozah |
| Shield Therapeutics INC | $130.44 | 2023-2025 | Accrufer |
| Janssen Pharmaceuticals, INC | $127.71 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $117.14 | 2020-2025 | Trelegy Ellipta |
| Pfizer INC. | $95.54 | 2020-2025 | |
| Abbvie INC. | $88.59 | 2022-2025 | |
| Lundbeck LLC | $66.45 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $52.36 | 2023-2025 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $52.18 | 2024 | Brixadi |
| Amgen INC. | $51.33 | 2024-2025 | Repatha, Otezla, Repatha |
| Alkermes, INC. | $49.24 | 2023 | Lybalvi |
| Merck Sharp & Dohme LLC | $45.86 | 2019-2022 | |
| Medtronic, INC. | $44.17 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $43.37 | 2023 | Rexulti |
| Avanir Pharmaceuticals, INC. | $40.09 | 2022 | |
| Novartis Pharmaceuticals Corporation | $36.84 | 2019-2021 | |
| Ucb, INC. | $34.82 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.96 | 2019 | |
| Werfen USA LLC | $17.56 | 2019 | |
| Lucid Diagnostics INC. | $17.36 | 2023 | |
| Acadia Pharmaceuticals INC | $17.09 | 2021 | |
| Sk Life Science, INC. | $15.52 | 2022 | |
| Neurelis, INC. | $14.64 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkat Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.